MediWound (MDWD) Misses Q4 EPS by 3c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NVDA
6. AMAT
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to MediWound (MDWD) Misses Q4 EPS by 3c, Revenues Beat

MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results

February 25, 2020 7:01 AM EST

Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA

Initiated U.S. Phase 2 adaptive design study of EscharEx for the treatment of venous leg ulcers

BARDA initiated the procurement of NexoBrid valued at $16.5 million for emergency response

Conference call begins today at 8:30 a.m. Eastern Time

YAVNE, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical... More